1. Introduction {#sec1}
===============

The human intestinal microbiome consists of a highly diverse microbial community ([@bib16]; [@bib58]). These microbes can interact with their host in a symbiotic relationship where the microbiome exerts beneficial effect on human health, and the host provides a suitable habitat for the microbes. Furthermore, the gut microbiome is considered a barrier against exogenous pathogenic bacteria by occupying adhesion sites on the mucosa, competing for nutrients, and producing antimicrobial compounds ([@bib53]; [@bib24]; [@bib7]). The human gut microbiome comprises numerous taxa of bacteria and yeast that may have probiotic properties, including *Lactobacillus* sp.*, Bifidbacterium* spp.*, Saccharomyces boulardii, Escherichia coli*, and *Enterococcus* sp., which are also used as probiotic supplements in products ([@bib18]). The intestinal microbiome of an adult person comprises approximately 100 species of bacteria which affect a variety of physiological functions ([@bib23]).

Bifidobacteria are anaerobic gram-positive bacteria, and their cell walls are composed of peptidoglycan and polysaccharide compounds ([@bib32]; [@bib12]). Bifidobacteria are the most common species of bacteria within a normal human intestinal community and are particularly common in newborns ([@bib59]). Several strains of the genus *Bifidobacterium* are considered probiotics because of their numerous beneficial effects on human health, including the prevention of infections with enteric pathogens, regulation of digestion, inhibition of colon cancer development, modulation of the immune system, anti-allergic properties, and protective effects against acute diarrhea ([@bib33]; [@bib28]). Diet, age, and the environment are known to affect colonization of the intestinal tract by bifidobacteria ([@bib56]).

Various probiotic supplements are widely applied in food products such as yogurt, fermented milk products, fermented juices, and freeze-dried supplements ([@bib46]). A previous study reported that probiotics did not enhance immune responses or affect general health and well-being ([@bib47]); however, a different study showed that probiotics in doses of up to 10^9^ and 2×10^9^ colony-forming units (CFU) can decrease infection risk ([@bib44]). Probiotics can stimulate the release of numerous kinds of immune mediators from different types of immune cells ([@bib51]), which affects both the innate and the adaptive branch of the immune system ([@bib19]). Cell wall components of probiotics and particularly those of bifidobacteria can stimulate nitric oxide synthase, which plays an important role in pathogen-infected cell death mechanisms elicited by macrophages through pro-inflammatory cytokine secretion ([@bib52]). A previous study showed that probiotics increase gut barrier functions through activating B cells followed by an effect on cytokine production, which stimulates the host\'s adaptive immune responses ([@bib1]). Few studies have so-far assessed potential effects of high doses of probiotic bacteria on systemic and mucosal immune responses. The objective of the current study was to assess the effects of two concentrations of bifidobacteria on immune responses in mice, assessed by gene expression of some mucosal immune factors and by measuring the levels of polyclonal immunoglobulins in serum samples.

2. Results {#sec2}
==========

2.1. Regulation of TLR2, IL4, IL10, and IFNγ gene expression following administration of different concentrations of bifidobacteria {#sec2.1}
-----------------------------------------------------------------------------------------------------------------------------------

TLR2, IFNγ, IL4, and IL10-mRNA expression profiles were compared between the treatment groups 10^8^*B* and 10^12^*B* and the control. A substantial and significant up-regulation of TLR2 gene expression was observed in mucosal immune cells of 10^8^*B* mice after 14, 28, and 42 days, compared to the control (*P* = 0.001, *P* = 0.0222, and *P* = 0.001, respectively). TLR2-mRNA showed an early down-regulation in mice of group 10^12^*B* after 14 days, which was, however, not statistically significant (*P* = 0.48); a non-significant elevation of this gene product was observed in the same treatment group on day 28, compared to the control (*P* = 0.094). TLR2 receptor gene expression was significantly down regulated in group 10^12^*B*, compared to the control (*P* = 0.0004) on day 42. TLR2 expression in mucosal immune cells after 14 and 42 days was also significantly up-regulated in group 10^8^*B* compared to group 10^12^*B* (*P \<* 0.001); however, this increase in group 10^8^*B* did not differ significantly from that in group 10^12^*B* on day 28 (*P* = 0.396; [Figure 1](#fig1){ref-type="fig"}).Figure 1Regulation of TLR2 gene expression in untreated and treated mice groups. *Where (C) represents untreated mice group (10*^*8*^*B) represent mice group treated with 10*^*8*^*CFU Bifidobacteria, and (10*^*12*^*B) represent mice group treated with 10*^*12*^*CFU Bifidobacteria. Total mRNA was isolated from the intestine of the indicated mouse strain and subjected to TLR2 qRT-PCR. (\*) Significant at P \< 0.05 as determined by analysis of variance, comparison was performed using One-factor ANOVA test. (\*) Comparison between control and treated groups. (\#) Comparison between the treated groups*.Figure 1

Group 10^8^*B* showed non-significant down-regulation in IFNγ-mRNA expression in the mucosa compared to the control group after 14 days (*P* = 0.748); however, IFNγ expression was significantly down-regulated in group 10^8^*B* after 28 and 42 days, compared to the control (*P* = 0.020 and *P* = 0.024, respectively). IFNγ-mRNA showed an earlier but non-significant increase in group 10^12^*B* compared to the control after 14 and 28 days (*P* = 0.08 and *P* = 0.108, respectively). After 42 days, IFNγ-mRNA expression in group 10^12^*B* was similar to that in the control (*P* = 0.876). The levels of IFNγ-mRNA expression showed a significant downregulation in group 10^8^*B* after 14, 28, and 42 days compared to those in group 10^12^*B* (*P* = 0.045, *P* = 0.0013, and *P* = 0.031, respectively; [Figure 2](#fig2){ref-type="fig"}).Figure 2Regulation of IFNγ gene expression in untreated and treated mice groups. *Where (C) represent untreated mice group (10*^*8*^*B) represent mice group treated with 10*^*8*^*CFU Bifidobacteria, and (10*^*12*^*B) represent mice group treated with 10*^*12*^*CFU Bifidobacteria. Total mRNA was isolated from the intestine of the indicated mouse strain and subjected to IFNγ qRT-PCR. (\*) Significant at P \< 0.05 as determined by analysis of variance, comparison was performed using One-factor ANOVA test. (\*) Comparison between controls and treated groups. (\#) Comparison between the treated groups.*Figure 2

IL4 gene expression was significantly down-regulated in mucosal immune cells of both group 10^8^*B* and 10^12^ *B* after 14, 28, and 42 days, compared to the control (*P* \< 0.001); IL4 was also significantly down-regulated in group 10^12^*B* after 14 and 42 days, compared to group 10^8^*B* (*P* = 0.002 and *P \<* 0.001, respectively), but it was significantly up-regulated in group 10^12^*B* relative to group 10^8^*B*, after 28 days *(P* = 0.030; [Figure 3](#fig3){ref-type="fig"}).Figure 3Regulation of IL4 gene expression in untreated and treated mice groups. *Where (C) represent untreated mice group (10*^*8*^*B) represent mice group treated with 10*^*8*^*CFU Bifidobacteria, and (10*^*12*^*B) represent mice group treated with 10*^*12*^*CFU Bifidobacteria. Total mRNA was isolated from the intestine of the indicated mouse strain and subjected to IL4 qRT-PCR. (\*) Significant at P \< 0.05 as determined by analysis of variance, comparison was performed using One-factor ANOVA test. (\*) Comparison between controls and treated groups. (\#) Comparison between the treated groups*.Figure 3

IL10-mRNA in group 10^8^*B* showed a highly significant increase after 14 and 28 days (*P* = 0.0092 and *P* = 0.0058, respectively) and a non-significant increase after 42 days (*P* = 0.4705), compared to the control; furthermore, expression of this cytokine gene indicated a non-significant increase in intestinal cells of group 10^12^*B* after 14 and 28 days, compared to the control (*P* = 0.241 and *P* = 0.28, respectively). IL10-mRNA expression in 10^12^*B* mice showed a significant decrease after 42 days, compared to the control (*P* = 0.042), and it increased non-significantly in group 10^8^*B* compared to group 10^12^*B* (*P* = 0.070) after 14 days; however, IL10-mRNA expression was significantly increased in mucosal cells of group 10^8^*B* compared to that in group 10^12^*B* after 28 and 42 days (*P* = 0.009 and *P* = 0.012, respectively; [Figure 4](#fig4){ref-type="fig"}).Figure 4Regulation of IL10 gene expression in untreated and treated mice groups. *Where (C) represent untreated mice group (10*^*8*^*B) represent mice group treated with 10*^*8*^*CFU Bifidobacteria, and (10*^*12*^*B) represent mice group treated with 10*^*12*^*CFU Bifidobacteria. Total mRNA was isolated from the intestine of the indicated mouse strain and subjected to IL10 qRT-PCR. (\*) Significant at P \< 0.05 as determined by analysis of variance, comparison was performed using One-factor ANOVA test. (\*) Comparison between controls and treated groups. (\#) Comparison between the treated groups.*Figure 4

2.2. Levels of polyclonal IgG, IgM, and IgA after exposure to different concentrations of bifidobacteria {#sec2.2}
--------------------------------------------------------------------------------------------------------

Systemic IgG, IgM, and IgA concentrations were compared between the treatment groups. Group 10^8^*B* showed a highly significant elevation in total IgG after 14 and 28 days, whereas after 42 days, the increase was non-significant, compared to the control (*P* = 0.000 and *P* = 0.152, respectively). Mice of group 10^12^ *B* showed a non-significant increase in IgG after 14 and 28 days, compared to the control (*P* = 0.47), however, this increase was significant on day 42 (*P* = 0.006). Polyclonal IgG concentrations were significantly higher in group 10^8^*B* than in group 10^12^*B* on days 14 and 28 (*P* \< 0.001) but were lower in 10^8^*B* than in 10^12^*B* after 42 days exposure to bifidobacteria, which was, however, not significant (*P* = 0.0791; [Figure 5](#fig5){ref-type="fig"}a).Figure 5Profile of total immunoglobulin in mice serum of treated and untreated groups. (a) represent polyclonal IgG, (b) represent polyclonal IgM, and (c) represent polyclonal IgA. *Where C represent the sera collected from untreated mice group, 10*^*8*^*B represent serum of mice collected post orally administration of 10*^*8*^*CFU Bifidobacteria, and 10*^*12*^*B serum of mice collected post orally administration of 10*^*12*^*CFU Bifidobacteria. Significant at p \< 0.05 as determined by analysis of variance, comparison was performed using One-factor ANOVA test. (\*) Comparison between controls and treated groups. (\#) Comparison between the treated groups.*Figure 5

[Figure 5](#fig5){ref-type="fig"} b shows early significant decreases in circulating polyclonal IgM concentrations in group 10^8^*B* on day 14 (*P* = 0.0007); non-significant IgM changes were recorded after 28 and 42 days in group 10^8^*B*, compared to the control (*P* = 0.24 and *P* = 0.131, respectively). IgM showed a highly significant increase in group 10^12^*B* after 14 and 28 days (*P* = 0.0026 and *P* = 0.017, respectively), however, the observed decrease on day 42 was non-significant, compared to the control (*P* = 0.424). Total IgM increased significantly in group 10^12^*B* after 14 and 28 days compared to group 10^8^*B* (*P =* 0.000and *P* = 0.043, respectively), whereas IgM levels in group 10^8^*B* did not differ from those in group 10^12^*B* after 42 days (*P* = 0.307).

IgA showed an early significant increase in groups 10^8^*B* and 10^12^*B* throughout the experiment, compared to the control (*P* = 0.000). Moreover, total IgA showed a highly significant increase in group 10^12^*B* compared to group 10^8^*B* after 14 days *(P =* 0.000), whereas no significant differences in IgA were observed between the two treatment groups after 28 and 42 days (*P* = 0.258 and *P* = 0.133, respectively; [Figure 5](#fig5){ref-type="fig"}c).

3. Discussion {#sec3}
=============

Bifidobacteria were recognized recently as potent probiotic agents with few side effects. Bacteria of this genus are necessary to maintain and improve health of normal intestinal epithelial cells, and they have been used to cure diarrhea and other digestive disorders ([@bib54]; [@bib49]; [@bib39]). Moreover, numerous probiotics electro-spun within various fiber compounds have been applied in different fields of biomedicine ([@bib2]). Notably, probiotics exert inhibitory effects on the germination of oral pathogenic bacteria and have been applied in treatments of mild to moderate periodontitis ([@bib10]; [@bib26]). This led to the question whether different bifidobacteria concentrations would affect immune responses in the intestinal mucosa of mice. TLR2 is considered one of the pattern-recognition receptors that facilitate recognition of gram-positive bacterial peptidoglycan ([@bib63]; [@bib6]; [@bib11]). Bifidobacteria act as immune-stimulators and immune-modulators through interactions with TLR2 ([@bib38]; [@bib63]). In the current study, TLR2-mRNA expression was significantly up-regulated in mucosal immune cells of group 10^8^*B* compared to group 10^12^ *B* and to the control. Furthermore, an earlier but non-significant difference in TLR2-mRNA receptor expression was observed between group 10^12^*B* and the control, followed by a significant downregulation at day 42, relative to the control. A previous study showed that probiotic bacteria or their antigenic particles can be internalized by dendritic cells or macrophages, which elicits signals to increase the number of TLR2 receptors ([@bib13]). Therefore, it seems possible that the effect of probiotic bacteria on immune cells involves TLR2, which may improve epithelial cell activation ([@bib21]; [@bib61]). In contrast, high concentrations of bifidobacteria such as 10^12^ CFU can exceed host mucosal immunity and therefore reduce beneficial effects of bifidobacteria, and unsuccessful internalized by dendritic cells or macrophages prevents signals that would otherwise increase the number of TLR2 receptors ([@bib20]; [@bib61]). Antigens administrated at low concentrations seemed more appropriate to achieve beneficial effects, which appeared to resemble the mechanisms of naturally occurring antigen inoculation more closely ([@bib15]). In the present study, changes in the expression of several fundamental immune modulator genes such as IFNγ, IL4, and IL10 were observed after treatment with 10^8^ CFU of bifidobacteria. For example, no up-regulation of IFNγ-mRNA gene expression was observed in mice treated with10^8^ CFU of bifidobacteria, compared to untreated mice, which was in line with the results of [@bib50] and confirmed similar observations made at a low concentration of bifidobacteria ([@bib14]). This down-regulation in IFNγ-mRNA may indicate inhibition of T-lymphocyte proliferation by probiotics such as bifidobacteria ([@bib49]). Down-regulation of IFNγ-mRNA expression can be associated with a decrease in inflammatory processes, and bifidobacteria are considered more suitable in the context of inflammatory diseases based on their lower inflammatory potential as indicated by poor induction of Th1 responses and IFNγ-mRNA expression ([@bib36]; [@bib42]). Substantial early up-regulation of IFNγ expression was observed in group 10^12^*B*, compared to group 10^8^*B* and to the control. This observation suggests that continuous exposure to high concentrations of bifidobacteria increased Th1 activation which led to an induction of IFNγ-mRNA generation and changes in immune responses towards inflammatory processes ([@bib57]; [@bib41]; [@bib49]). A previous study found that oral treatment with probiotics increased Th1 cytokines but inhibited Th2 cytokines in some atopic children ([@bib43]). Similarly, we observed significant downregulation of IL4 gene expression in groups 10^8^*B* or 10^12^*B*, compared to untreated mice; however, the highest concentration treatment (10^12^ CFU) produced a more significant downregulation in IL4-mRNA expression compared to mice treated with 10^8^ CFU, regardless of treatment time. In line with our results, *Lactobacillus* probiotic stimulation reduced concentrations of pro- and anti-inflammatory cytokines including IL2, TNFα, and IL4, and entirely reduced IL12 and TGFβ in cultured human peripheral blood mononuclear cells after 96 h of incubation ([@bib3]). IL10 is produced by numerous different immune cell populations such as macrophages, monocytes, DCs, B, Th2, Th1, and T~reg~ cells ([@bib35]; [@bib30]; [@bib37]; [@bib45]), however, also non-immune effector cell types such as epithelial cells and keratinocytes can produce IL10 in response to infection, tissue damage, or tumor genesis ([@bib29]). In the current study, substantial up-regulation of IL10 expression was observed in group 10^8^*B*, compared to group 10^12^*B* and to the control, whereas no difference was observed between group 10^12^B and the control. Similarly, different species of the genus *Lactobacillus* primed monocyte-derived dendritic cells to maturation of T~reg~ cells, which augmented levels of IL10 and prevented proliferation of T cells in an IL10 concentration-dependent manner ([@bib55]). IL10 gene expression observed in the present study may be due to a stimulation of intestinal CD103 + dendritic cells to produce IL10 and IL27 via the TLR2/MyD88 pathway in the large intestine after administration of bifidobacteria, particularly regarding *B. breve*. This species has been used to prevent intestinal inflammation through the induction of intestinal IL10 producing Tr1 cell ([@bib27]). However, down-regulation of TLR2 gene expression in the current study directly affected IL10 production due to high concentrations of bifidobacteria (10^12^ CFU; [@bib20]; [@bib61]).

Increased levels of total antibodies, particularly IgM and IgG, may be interpreted as an activation of the specific immune response, mainly caused by the activation of T and B lymphocytes ([@bib17]; [@bib21]). Moreover, *Lactobacillus* strains influence the production of several types of immunoglobulins, particularly of IgG and IgA ([@bib17]). In the present study, mice exposed to 10^8^ CFU of bifidobacteria showed an early and highly significant elevation in polyclonal IgG concentrations, compared to group 10^12^*B* and to the control; however, total IgM levels in group 10^8^*B* did not differ significantly from those in untreated mice, throughout the experiment. Although group 10^12^*B* showed a significant increase in total IgG at a late point in time (day 42), compared to untreated mice, a highly significant increase in IgM levels was observed in this group compared to group 10^8^*B* and to the control. Remarkably, probiotic bacteria consolidate the systemic antibody response, depending on the type of antigen, where some antigens activated this immune response whereas others did not ([@bib22]). Natural serum IgM is generated by B cells and exerts a wide range of functions; these antibodies commonly bind with low affinity to bacterial antigens, including lipopolysaccharides and capsular polysaccharides ([@bib5]; [@bib9]), also because natural IgM antibodies stimulate the induction of IgG specific to bacterial and viral antigens ([@bib62]; [@bib9]). Interestingly, in the present study, polyclonal IgA increased significantly in both treatment groups after 7 days compared to the control, throughout the experiment Interestingly, in the present study, an earlier significant increase in the polyclonal IgA was detected in both treatment groups compared to the control, where the total IgA was also significantly increased in the high-concentration treatment (10^12^ CFU), compared to the low-concentration treatment (10^8^ CFU). Numerous previous studies confirmed a significant increase in polyclonal IgA after exposure to various probiotics, particularly bifidobacteria, due to an increasing number of IgA-producing cells, which depended on the bacterial strain ([@bib25]; [@bib60]). This may be related to a concomitant increase in total IgG and IgM levels ([@bib57]), and bifidobacteria and lipopolysaccharides can non-specifically enhance B lymphocyte proliferation and increase antibody synthesis from lymphocytes by activating the stimulation IL5 cytokine, which in turn stimulates an increase in IgA ([@bib31]). Our study revealed that probiotics can improve the defense function of epithelial cells by inducing secretion of cytokines and production of immunoglobulins and antimicrobial compounds ([@bib8]).

4. Conclusion {#sec4}
=============

To our knowledge, this is the first comprehensive study to assess the effects of high concentrations of bifidobacteria on mucosal immune responses. We found that administration of high doses of bifidobacteria (10^12^ CFU) elicits undesirable activation of both innate and adaptive immunity, in contrast to 10^8^ CFU bifidobacteria treatments. Overall, substantial differences were observed between the treatments, and exposure to 1012 CFU of bifidobacteria down-regulated gene expression of TLR2 and IL10 but significantly up-regulated IFNγ-mRNA. Our findings suggest a drift of mucosal immune responses towards inflammatory processes; however, both applied dosages of bifidobacteria can stimulate the production of total immunoglobulins, particularly of IgA.

5. Materials and methods {#sec5}
========================

5.1. Bifidobacteria strains {#sec5.1}
---------------------------

Five strains of bifidobacteria (*B. lactis*, *B. longum, B. bifidum, B. infantis,* and *B. breve*) were obtained in powdered form from Custom Probiotics Inc, USA and the bacteria were prepared according to the manufacturer\'s instructions ([@bib4]; [@bib48]).

5.2. Study animals and experimental design {#sec5.2}
------------------------------------------

Forty female Swiss mice were recruited at an age of eight weeks and were kept under standard laboratory conditions at the Center of King Fahad for Medical Research of the King Abdul-Aziz University in Jeddah, Saudi Arabia. Individuals weighed about 30--35 g. The mice were assigned to three treatment groups: group 10^8^*B* comprised 15 mice that were treated with 0.5 ml medium containing 10^8^ CFU of bifidobacteria, three times per week; group 10^12^*B* comprised 15 mice that received 0.5 ml medium containing 10^12^ CFU of bifidobacteria, three times per week; a control group of ten individuals. Bacteria were administered by oral gavage. Five mice of each group were sacrificed 14, 28, and 42 days after the start of the experiment. Intestinal tissue and serum samples were stored at -80 °C until laboratory analyses.

Animal experiments were approved by the Scientific Research Ethical Committee of the Faculty of Science, King Abdulaziz University and King Abdulaziz City for Science and Technology (KACST), Jeddah, KSA.

5.3. TLR2, IFNγ, IL4, and IL10 gene expression {#sec5.3}
----------------------------------------------

Samples of intestinal tissue were submerged in RNA*later* (QIAGEN, Cat NO.76106) to prevent RNA degradation; after this, total RNA was isolated using the RNeasy Maxi kit (QIAGEN, Cat No. 75162), according to the manufacturer\'s instructions. RNA was eluted using RNase-free water, and RNA samples were aliquoted and stored at -80 °C until analyses. RNA was quantified and subsequently amplified using Verso SYBR Green 1-Step qRT-PCR Kit Master Mix reagents (Thermo Scientific, Cat No. AB-4108/C). Each reaction mixture for qRT-PCR was performed in one individual tube, according to the manufacturer\'s instructions. Primer sequences are shown in [Table 1](#tbl1){ref-type="table"}; each set of primers was added to a one-step RT-PCR mixture for each target gene. The total PCR reaction mixture was adjusted to 25 μl and contained 12.5 μl Verso SYBER Green master mix, 0.25 μl Verso enzyme, 0.25 mM of each primer, and 400--500 ng RNA; cDNA of the target genes was transcribed at 50 °C for 30 min, followed by 40 cycles of 95 °C for 15 s, 58--62 °C for 30 s, and 72 °C for 30 s. A commercially available real-time PCR detection system (CFX Connect™ Real-Time PCR, Bio-Rad) was used to quantify the amplified products based on continuously increasing fluorescence emission during PCR amplification. Relative mRNA quantification was calculated according to the 2-ΔΔCt method. The same calibrator sample was employed for all measurements ([@bib34]; [@bib40]).Table 1Primers used in the evaluation of TLR2, IFNγ, IL4, and IL10 genes expression extracted from mice mucosal intestine.Table 1GenePolarityPrimer sequence (5\'\-\--\'3)Primer lengthNucleotide positionsReference Gene**β** ActinSenseTATTGGCAACGAGCGG16856--871[NM_007393](ncbi-n:NM_007393){#intref0010}AntisenseCGGATGTCAACGTCAC16978--963TLR2SenseAACCTCAGACAAAGCGTCAAATC23797--816[NM_011905](ncbi-n:NM_011905){#intref0015}AntisenseACCAAGATCCAGAAGAGCCAAA22993--974IFNγSenseGGCCATCAGCAACAACATAAGCGT24321--344[NM_008337](ncbi-n:NM_008337){#intref0020}AntisenseTGGGTTGTTGACCTCAAACTTGGC24415--438IL4SenseAGATGGATGTGCCAAACGTCCTCA24205--228[NM_021283](ncbi-n:NM_021283){#intref0025}AntisenseAATATGCGAAGCACCTTGGAAGCC24269--292IL10SenseAGAGAAGCATGGCCCAGAAATC22336--357[NM_010548](ncbi-n:NM_010548){#intref0030}AntisenseTCATGGCCTTGTAGACACCTTG22521--542

5.4. Measurement of total IgA, IgM, and IgG in serum using a capture enzyme-linked immunosorbent assay (ELISA) {#sec5.4}
--------------------------------------------------------------------------------------------------------------

Polyclonal IgG, IgM, and IgA concentrations were measured in serum samples using capture ELISA quantitation kits (Abcame, United Kingdom, Cat. nos. ab157717, ab133047, and ab157719, respectively) according to the manufacturer\'s instructions. Absorbance was measured at 450 nm, and antibody concentrations were then determined according to standard curves produced by assaying standards of the respective immunoglobulin. Color intensity of the assay is proportional to the amount of specific antibody, and total serum immunoglobulin concentration was calculated as the sum of the respective IgA, IgM, and IgG concentrations.

5.5. Statistical analyses {#sec5.5}
-------------------------

The statistical analysis was accomplished between the untreated as well as two treated groups using MegaStat software version 10.1, and the one-way ANOVA parametric test. Statistical significance is reported at *P* \< 0.05.
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